Regulation of Airway Epithelial-Derived Alarmins in Asthma: Perspectives for Therapeutic Targets

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2024 Oct 26

PMID 39457624

Authors

Ravneet K Hansi

Maral Ranjbar

Christiane E Whetstone

Gail M Gauvreau

Affiliations

Soon will be listed here.

Abstract

Asthma is a chronic respiratory condition predominantly driven by a type 2 immune response. Epithelial-derived alarmins such as thymic stromal lymphopoietin (TSLP), interleukin (IL)-33, and IL-25 orchestrate the activation of downstream Th2 cells and group 2 innate lymphoid cells (ILC2s), along with other immune effector cells. While these alarmins are produced in response to inhaled triggers, such as allergens, respiratory pathogens or particulate matter, disproportionate alarmin production by airway epithelial cells can lead to asthma exacerbations. With alarmins produced upstream of the type 2 inflammatory cascade, understanding the pathways by which these alarmins are regulated and expressed is critical to further explore new therapeutics for the treatment of asthmatic patients. This review emphasizes the critical role of airway epithelium and epithelial-derived alarmins in asthma pathogenesis and highlights the potential of targeting alarmins as a promising therapeutic to improve outcomes for asthma patients.

Citing Articles

Unlocking Better Asthma Control: A Narrative Review of Adherence to Asthma Therapy and Innovative Monitoring Solutions.

Poplicean E, Crisan A, Tudorache E, Hogea P, Mladin R, Oancea C J Clin Med. 2024; 13(22).

PMID: 39597843 PMC: 11594773. DOI: 10.3390/jcm13226699.

References

Sverrild A, Hansen S, Hvidtfeldt M, Clausson C, Cozzolino O, Cerps S . The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM). Eur Respir J. 2021; 59(1). DOI: 10.1183/13993003.01296-2021. View

Soumelis V, Reche P, Kanzler H, Yuan W, Edward G, Homey B . Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol. 2002; 3(7):673-80. DOI: 10.1038/ni805. View

Rochman I, Watanabe N, Arima K, Liu Y, Leonard W . Cutting edge: direct action of thymic stromal lymphopoietin on activated human CD4+ T cells. J Immunol. 2007; 178(11):6720-4. DOI: 10.4049/jimmunol.178.11.6720. View

Zou W, Ye D, Liu S, Hu J, Zhu T, He F . GSK-3β Inhibitors Attenuate the PM2.5-Induced Inflammatory Response in Bronchial Epithelial Cells. Int J Chron Obstruct Pulmon Dis. 2021; 16:2845-2856. PMC: 8523522. DOI: 10.2147/COPD.S327887. View

Osei E, Mostaco-Guidolin L, Hsieh A, Warner S, Al-Fouadi M, Wang M . Epithelial-interleukin-1 inhibits collagen formation by airway fibroblasts: Implications for asthma. Sci Rep. 2020; 10(1):8721. PMC: 7250866. DOI: 10.1038/s41598-020-65567-z. View

Corren J, Karpefors M, Hellqvist A, Parnes J, Colice G . Tezepelumab Reduces Exacerbations Across All Seasons in Patients with Severe, Uncontrolled Asthma: A Post Hoc Analysis of the PATHWAY Phase 2b Study. J Asthma Allergy. 2021; 14:1-11. PMC: 7810672. DOI: 10.2147/JAA.S286036. View

Jin J, Sunusi S, Lu H . Group 2 innate lymphoid cells (ILC2s) are important in typical type 2 immune-mediated diseases and an essential therapeutic target. J Int Med Res. 2022; 50(1):3000605211053156. PMC: 8796086. DOI: 10.1177/03000605211053156. View

Vacca F, Chauche C, Jamwal A, Hinchy E, Heieis G, Webster H . A helminth-derived suppressor of ST2 blocks allergic responses. Elife. 2020; 9. PMC: 7234810. DOI: 10.7554/eLife.54017. View

Wechsler M, Colice G, Griffiths J, Almqvist G, Skarby T, Piechowiak T . SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma. Respir Res. 2020; 21(1):264. PMC: 7550846. DOI: 10.1186/s12931-020-01503-z. View

10.

Whetstone C, Cusack R, Price E, Howie K, Stevens C, Al-Sajee D . Effect of benralizumab on inflammation in skin after intradermal allergen challenge in patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol Glob. 2024; 3(4):100310. PMC: 11372810. DOI: 10.1016/j.jacig.2024.100310. View

11.

Li J, Kanju P, Patterson M, Chew W, Cho S, Gilmour I . TRPV4-mediated calcium influx into human bronchial epithelia upon exposure to diesel exhaust particles. Environ Health Perspect. 2011; 119(6):784-93. PMC: 3114812. DOI: 10.1289/ehp.1002807. View

12.

Kayalar O, Rajabi H, Konyalilar N, Mortazavi D, Aksoy G, Wang J . Impact of particulate air pollution on airway injury and epithelial plasticity; underlying mechanisms. Front Immunol. 2024; 15:1324552. PMC: 10957538. DOI: 10.3389/fimmu.2024.1324552. View

13.

Vatrella A, Maglio A, Pelaia C, Ciampo L, Pelaia G, Vitale C . Eosinophilic inflammation: An Appealing Target for Pharmacologic Treatments in Severe Asthma. Biomedicines. 2022; 10(9). PMC: 9496162. DOI: 10.3390/biomedicines10092181. View

14.

Smithgall M, Comeau M, Yoon B, Kaufman D, Armitage R, Smith D . IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol. 2008; 20(8):1019-30. DOI: 10.1093/intimm/dxn060. View

15.

Allinne J, Scott G, Lim W, Birchard D, Erjefalt J, Sanden C . IL-33 blockade affects mediators of persistence and exacerbation in a model of chronic airway inflammation. J Allergy Clin Immunol. 2019; 144(6):1624-1637.e10. DOI: 10.1016/j.jaci.2019.08.039. View

16.

Stirling R, van Rensen E, Barnes P, Chung K . Interleukin-5 induces CD34(+) eosinophil progenitor mobilization and eosinophil CCR3 expression in asthma. Am J Respir Crit Care Med. 2001; 164(8 Pt 1):1403-9. DOI: 10.1164/ajrccm.164.8.2010002. View

17.

Deiteren A, Bontinck L, Conickx G, Vigan M, Dervaux N, Gassiot M . A first-in-human, single and multiple dose study of lunsekimig, a novel anti-TSLP/anti-IL-13 NANOBODY® compound, in healthy volunteers. Clin Transl Sci. 2024; 17(6):e13864. PMC: 11196376. DOI: 10.1111/cts.13864. View

18.

Zhang J, Zhang D, Pan Y, Liu X, Xu J, Qiao X . The TL1A-DR3 Axis in Asthma: Membrane-Bound and Secreted TL1A Co-Determined the Development of Airway Remodeling. Allergy Asthma Immunol Res. 2022; 14(2):233-253. PMC: 8914606. DOI: 10.4168/aair.2022.14.2.233. View

19.

Shinkai M, Ebisawa M, Fukushima Y, Takeuchi S, Okada H, Tokiyo T . One-year safety and tolerability of tezepelumab in Japanese patients with severe uncontrolled asthma: results of the NOZOMI study. J Asthma. 2022; 60(3):616-624. DOI: 10.1080/02770903.2022.2082309. View

20.

Busse W, Holgate S, Kerwin E, Chon Y, Feng J, Lin J . Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med. 2013; 188(11):1294-302. DOI: 10.1164/rccm.201212-2318OC. View